Horizon Therapeutics Competitors and Similar CompaniesClear all
Roivant Sciences's competitors and similar companies include Amarin, Cartesian Therapeutics, Ultragenyx, Avrobio, Arcturus Therapeutics and Aeglea.
 Amarin Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases. |  Cartesian Therapeutics Cartesian Therapeutics (formerly Selecta Biosciences) is a clinical-stage biopharmaceutical company advancing a differentiated product pipeline to modulate the immune system. |  Avrobio Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. |  Arcturus Therapeutics Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company. |  Aeglea Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics. | |||
Founding Date | Founding Date 2014 | Founding Date 1991 | Founding Date 2007 | Founding Date 2010 | Founding Date N/A | Founding Date 2013 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations London, GB HQ Basel, CH Boston, US New York, US | Locations Dublin, IE HQ Zug, CH Bridgewater Township, US | Locations Watertown, US HQ | Locations Cambridge, US HQ | Locations San Diego, US HQ | Locations Austin, US HQ | |
Employees | Employees 908 | Employees 275 | Employees 15 | Employees 1,2763% decrease | Employees 8573% increase | Employees 170 | Employees 6932% decrease |
Valuation ($) | Valuation ($) 8.8 b | Valuation ($) 257.6 m | Valuation ($) 536.3 m | Valuation ($) 4.9 b | Valuation ($) 5.2 m | Valuation ($) 529.2 m | Valuation ($) 48.6 m |
Financial | |||||||
Revenue (est.) | Revenue (est.) $29.1m (FY, 2024) | Revenue (est.) $228.6m (FY, 2024) | Revenue (est.) $38.9m (FY, 2024) | Revenue (est.) $560.2m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $152.3m (FY, 2024) | Revenue (est.) N/A |
Net income | Net income ($356.7m) (FY, 2024) | Net income ($82.2m) (FY, 2024) | Net income ($77.4m) (FY, 2024) | Net income ($569.2m) (FY, 2024) | Net income ($58m) (FY, 2024) | Net income ($80.9m) (FY, 2024) | Net income ($208m) (FY, 2024) |
Funding | |||||||
Total funding raised | Total funding raised $ 1.9b | Total funding raised $ 122.8m | Total funding raised $ 167.7m | Total funding raised $ 200.1m | Total funding raised $ 85m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Amarin
HQ
Dublin, IE
Employees
275
Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases.
View companyCartesian Therapeutics
HQ
Watertown, US
Employees
15
Cartesian Therapeutics (formerly Selecta Biosciences) is a clinical-stage biopharmaceutical company advancing a differentiated product pipeline to modulate the immune system.
View company
Ultragenyx
HQ
Novato, US
Employees
1,276↓ 3% decrease
Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.
View companyAvrobio
HQ
Cambridge, US
Employees
85
Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
View company